Based on these data, we found that SPHK1 was overexpressed in thirteen cancer types, including breast invasive carcinoma (BRCA, Log(FC) = 0.52, p < 0.001), head and neck squamous cell carcinoma (HNSC; Log(FC) = 1.30, p < 0.001), liver hepatocellular carcinoma (LIHC; Log(FC) = 1.23, p = 0.002), lung squamous cell carcinoma (LUSC; Log(FC) = 1.32, p < 0.001), and thyroid carcinoma (THCA; Log(FC) = 1.17, p < 0.001). Here, SPHK1 is linked to cancer.